Jerry Harb1, Pen-Jen Lin1, Jijun Hao2,3. 1. Graduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA, 91766, USA. 2. Graduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA, 91766, USA. jhao@westernu.edu. 3. College of Veterinary Medicine, Western University of Health Sciences, 309 E 2nd Street, Pomona, CA, 91766, USA. jhao@westernu.edu.
Abstract
PURPOSE OF REVIEW: Review current understanding of both canonical and non-canonical Wnt signaling in cancer and provide updated knowledge in current clinical trials of Wnt signaling drugs. RECENT FINDINGS: Important roles of both canonical and non-canonical Wnt signaling in cancer have been increasingly recognized. Recent clinical trials of several Wnt-signaling drugs have showed promising outcomes. In addition, some drugs that were originally approved for the treatment of other diseases have been recently found to block Wnt signaling, highlighting their potential to treat Wnt-dependent cancer. Dysfunction of Wnt signaling is implicated in cancer, and targeting Wnt signaling represents a useful approach to treat cancer. Current clinical trials of Wnt signaling drugs have showed promising outcomes, and repurposing the previously approved drugs for other diseases to treat Wnt-dependent cancer requires further studies.
PURPOSE OF REVIEW: Review current understanding of both canonical and non-canonical Wnt signaling in cancer and provide updated knowledge in current clinical trials of Wnt signaling drugs. RECENT FINDINGS: Important roles of both canonical and non-canonical Wnt signaling in cancer have been increasingly recognized. Recent clinical trials of several Wnt-signaling drugs have showed promising outcomes. In addition, some drugs that were originally approved for the treatment of other diseases have been recently found to block Wnt signaling, highlighting their potential to treat Wnt-dependent cancer. Dysfunction of Wnt signaling is implicated in cancer, and targeting Wnt signaling represents a useful approach to treat cancer. Current clinical trials of Wnt signaling drugs have showed promising outcomes, and repurposing the previously approved drugs for other diseases to treat Wnt-dependent cancer requires further studies.
Authors: C J Smith; Y Zhang; C M Koboldt; J Muhammad; B S Zweifel; A Shaffer; J J Talley; J L Masferrer; K Seibert; P C Isakson Journal: Proc Natl Acad Sci U S A Date: 1998-10-27 Impact factor: 11.205
Authors: Rebecca C Arend; Angelina I Londoño-Joshi; Rajeev S Samant; Yonghe Li; Michael Conner; Bertha Hidalgo; Ronald D Alvarez; Charles N Landen; J Michael Straughn; Donald J Buchsbaum Journal: Gynecol Oncol Date: 2014-04-13 Impact factor: 5.482
Authors: Kyung-Eun Lim; April M Hoggatt; Whitney A Bullock; Daniel J Horan; Hiroki Yokota; Frederick M Pavalko; Alexander G Robling Journal: J Cell Physiol Date: 2020-06-11 Impact factor: 6.384
Authors: Allison E Norlander; Melissa H Bloodworth; Shinji Toki; Jian Zhang; Weisong Zhou; Kelli Boyd; Vasiliy V Polosukhin; Jacqueline-Yvonne Cephus; Zachary J Ceneviva; Vivek D Gandhi; Nowrin U Chowdhury; Louis-Marie Charbonnier; Lisa M Rogers; Janey Wang; David M Aronoff; Lisa Bastarache; Dawn C Newcomb; Talal A Chatila; R Stokes Peebles Journal: J Clin Invest Date: 2021-04-01 Impact factor: 14.808
Authors: Na Hui Kim; Minji Kwon; Jiwoo Jung; Hyo Byeong Chae; Jiwoo Lee; Yeo-Jun Yoon; In Seok Moon; Ho K Lee; Wan Namkung; Konstantina M Stankovic; Se A Lee; Jong Dae Lee; Sin-Aye Park Journal: Acta Pharmacol Sin Date: 2022-04-27 Impact factor: 6.150